Kopfbereich

additional navigation

You are here:

AOP Orphan United Kingdom


AOP Orphan Pharmaceuticals AG

The United Kingdom (UK) is the 9th largest pharmaceutical market in the World and ranks 4th largest in Europe.  With R&D expenditure at over £4 billion per annum, the highest in Europe, the UK is at the forefront of pharmaceutical innovation. It is also the home of European Medicines Agency (EMA) and the National Institute for Health and Care Excellence (NICE), one of the World’s leading authorities on Health Technology Assessment (HTA). Moreover with London as the World’s financial centre, its strong global communications and transport links and favourable business environment, the UK has become a hub for pharmaceutical companies in US and Japan seeking partners in Europe. 

In recognition of UKs strategic position within global pharmaceutical market AOP Orphan established a representative office near London in 2009. Led by Douglas Lloyd-Fell AOPs UK office has expanded the Company’s business development activities and laid the foundations for local commercial operations, culminating in the formation of AOP Orphan Limited in 2012. 

Today the company markets products in the UK for substance misuse and for the control of heart rate and blood pressure during surgery and in the intensive care setting. Plans are well advanced to expand the portfolio further with the addition of products to treat rare neurological conditions and for patients with HIV associated lipodystrophy in the next 12 months.   

Contact

AOP Orphan Pharmaceuticals AG
1 Furzeground Way UB11 1BD Uxbridge, Middlesex
United Kingdom
Tel +44 20 86223029
Fax +44 20 86223200
office.uk(at)aoporphan.com